by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

HealthPartners Neuroscience Center Research and Innovation Warning Letter Details

Warning Letter

HealthPartners Neuroscience Center Research and Innovation

Recipient Name Leah R. Hanson, Ph.D., Recipient Title Senior Director, Neuroscience Research, HealthPartners Neuroscience Center Research and Innovation, 295 Phalen Boulevard Saint Paul , MN 55130-2455 United States

Issue DateMay 19, 2026

FEI NumberN/A

Violations4

CountryUnited States

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

HealthPartners Neuroscience Center Research and Innovation FDA Warning Letter, May 19, 2026